More than 800 myeloma samples have been recruited to the Horizon 2020 project, MMPredict

Myeloma Patients Europe (MPE) is participating in the Horizon 2020 project, MMPredict, aimed at developing a personalised medicine tool to predict the most effective treatment strategy for individual myeloma patients. The MMpredict consortium has reached a new milestone in this project by completing the recruitment of the patient samples required in this project. With more than 800 myeloma samples recruited, the project team meets its aimed target population. The current efforts will now be focused…

Open call to participate in the Advocate Development Programme (ADP)

Patient input into medical research is becoming increasingly important. The MPE Advocate Development Programme aims to help myeloma and AL amyloidosis advocates understand the research and development process of drugs, from the preclinical stages through to post-marketing surveillance and national access. Topics include clinical trial design, regulation, pricing and health technology assessment (HTA). The programme combines a series of theoretical sessions delivered by experts with practical sessions that take place during the most important myeloma…